Chromosome 8q amplification, a common genomic alteration in hepatocellular carcinoma (HCC), includes the gene TATA-box binding protein–associated factor 2 (TAF2), a key component of the TFIID basal transcription complex. This study demonstrates that TAF2 is overexpressed in human HCC tissues and cell lines, and higher expression correlates with poorer overall survival.
Chromosome 8q amplification, a common genomic alteration in hepatocellular carcinoma (HCC), includes the gene TATA-box binding protein–associated factor 2 (TAF2), a key component of the TFIID basal transcription complex. This study demonstrates that TAF2 is overexpressed in human HCC tissues and cell lines, and higher expression correlates with poorer overall survival.
Using hepatocyte-specific TAF2 knockout mice, investigators showed that loss of TAF2 leads to hepatocyte death, compensatory proliferation, inflammation, and fibrosis, creating a microenvironment favorable for tumor development. Consequently, DEN/high-fat high-sugar diet–induced HCC was markedly increased in TAF2-deficient mice.
Conversely, TAF2 overexpression alone did not initiate liver tumors, but significantly enhanced MYC-driven hepatocarcinogenesis, suggesting that TAF2 acts as a tumor promoter rather than a primary oncogenic driver.
Mechanistically, TAF2 binds promoter regions of tumor-promoting genes and non-coding RNAs, enhancing transcription programs that support cancer hallmarks such as proliferation and survival.
Key Message:
TAF2 plays a central role in maintaining hepatocyte viability and can accelerate hepatocarcinogenesis in the presence of oncogenic signals, highlighting it as a potential biomarker and therapeutic target in HCC.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.